As of Aug 26
| +0.72 / +3.37%|
The 7 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 27.00, with a high estimate of 37.00 and a low estimate of 24.00. The median estimate represents a +22.34% increase from the last price of 22.07.
The current consensus among 7 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.